Vivifrail Exercise Program in Nonagenarians: Effects on Function, Muscle, and Cognition (Vivifrail)
Effects of a Multicomponent Exercise Program Based on the Vivifrail Protocol on Functional Capacity, Muscle Morphology, and Cognition in Nonagenarians: A Randomized Clinical Trial
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a three-arm, parallel-group randomized controlled trial evaluating a home-based multicomponent exercise program based on the Vivifrail protocol in community-dwelling nonagenarians (aged 90 years or older). A total of 54 participants (18 per group) will be randomly allocated to one of three groups: G1, performing the Vivifrail program at least twice a week; G2, performing it at least three times a week; or a control group (GC) maintaining usual activities.
Randomization will be performed using Randomizer software (www.randomizer.org) by an independent researcher not involved in the assessments. Allocation is stratified by sex and by baseline functional level, defined by collapsing the six Vivifrail functional categories into two groups (lower function: Types A, B, and B+; higher function: Types C, C+, and D), to ensure balanced distribution of baseline physical function across the three groups. Each participant is still assigned the individualized Vivifrail training passport corresponding to their specific functional category. Given the autonomous, home-based nature of the intervention, participants and interventionists cannot be blinded; however, outcome assessors remain blinded to group allocation throughout the study.
Assessments occur at three timepoints: baseline (T0), 12 weeks (T1), and 24 weeks (T2). The 24-week intervention is individualized according to each participant's functional profile, determined by the Short Physical Performance Battery (SPPB) and the corresponding Vivifrail training passport.
The primary outcome is physical function measured by the total SPPB score (0-12). Secondary outcomes include mobility (Timed Up and Go and cognitive dual-task cost), handgrip strength, lower-limb power (five-times sit-to-stand with linear encoder), gait speed, balance, muscle morphology of the vastus lateralis (ultrasound), cognition (Mini-Mental State Examination), and change in Vivifrail functional category. Data will be analyzed by intention to treat using generalized estimating equations (GEE), examining the group-by-time interaction.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brésil, 90035-903
- Hospital de Clínicas de Porto Alegre (HCPA) - Geriatrics outpatient clinic
-
Porto Alegre, Rio Grande do Sul, Brésil, 90690-200
- Escola de Educação Física, Fisioterapia e Dança (ESEFID/UFRGS) - and participants' homes
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Aged 90 years or older
- Living in the community (own or family home)
- Able to walk independently or with a walking aid (cane or walker), without third-party assistance
- Minimum cognitive capacity to understand and perform the exercises (MMSE, education-adjusted cutoffs)
- Adequate home conditions to perform the program
- Availability of a family member or caregiver to support the sessions
- Signed informed consent (with legal guardian assistance when needed)
Exclusion Criteria:
- - Total inability to walk or permanent bedridden condition
- Severe cognitive impairment preventing safe understanding and execution of exercises
- Severe orthopedic, neurological, or rheumatological conditions preventing exercise
- Concurrent participation in another structured exercise program
- Anticipated unavailability (relocation, planned hospitalization, or institutionalization) during the intervention
- Refusal to sign informed consent or absence of a legal guardian when required
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Vivifrail - 2 sessions/week (G1)
Home-based Vivifrail multicomponent exercise program performed at least twice a week for 24 weeks, individualized by functional profile (SPPB and Vivifrail passport).
|
Individualized multicomponent home-based training (strength/power, balance, gait, and flexibility) prescribed according to the participant's Vivifrail functional profile.
|
|
Expérimental: Vivifrail - 3 sessions/week (G2)
Home-based Vivifrail multicomponent exercise program performed at least three times a week for 24 weeks, individualized by functional profile.
|
Individualized multicomponent home-based training (strength/power, balance, gait, and flexibility) prescribed according to the participant's Vivifrail functional profile.
|
|
Aucune intervention: Control (GC)
Participants maintain usual activities without a structured exercise program during the 24-week period.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in physical function measured by the Short Physical Performance Battery (SPPB) total score
Délai: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Total SPPB score ranging from 0 to 12 points (higher scores indicate better lower-extremity physical function), combining balance, gait speed, and chair-stand tests.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mobility - Timed Up and Go (TUG)
Délai: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
ime in seconds to rise, walk 3 meters, turn, return, and sit.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
|
Mobility under dual task - Cognitive TUG and dual-task cost (DTC%) ·
Délai: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
TUG performed with a concurrent cognitive task; dual-task cost calculated as percentage change relative to single-task TUG.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Handgrip strength
Délai: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
Maximal isometric handgrip strength in kilograms, measured with a Jamar dynamometer.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Lower-limb muscle power - Five-times sit-to-stand
Délai: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
ime in seconds and estimated lower-limb power measured during the five-times sit-to-stand test using a linear encoder.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Gait speed
Délai: aseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
Usual gait speed in meters per second.
|
aseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Balance
Délai: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
Static balance assessed by the SPPB balance component (side-by-side, semi-tandem, and tandem stands).
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Change in Vastus Lateralis Muscle Thickness
Délai: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Vastus lateralis muscle thickness measured by B-mode ultrasound, defined as the distance between the adipose-muscle and muscle-bone interfaces, analyzed in ImageJ by a single trained, blinded assessor.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
|
Change in Vastus Lateralis Echo Intensity (Muscle Quality)
Délai: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Muscle quality assessed by echo intensity on B-mode ultrasound, expressed in arbitrary units (grayscale, 0-255) via manual region-of-interest analysis in ImageJ, excluding fascia and bone.
Higher echo intensity indicates greater intramuscular fat/fibrous infiltration, i.e., poorer muscle quality.
Single assessor blinded to group allocation.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
|
Cognition - Mini-Mental State Examination (MMSE)
Délai: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Global cognitive function measured by the MMSE, using education-adjusted cutoffs.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
|
Change in Vivifrail functional category
Délai: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Transition across Vivifrail functional categories (Types A, B, B+, C, C+, D) over the intervention period.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 79748517.5.0000.5347
- U1111-1343-8083 (Autre identifiant: WHO Universal Trial Number (UTN))
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .